The different formulations of ONS effects on adenocarcinoma of the Esophagogastric Junction patients with preoperative concurrent chemoradiotherapy with intestinal barrier

The different formulations of ONS effects on adenocarcinoma of the Esophagogastric Junction patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005329

Enrollment

Unknown

Registered

2014-09-27

Start date

2014-10-15

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the Esophagogastric Junction

Interventions

TPF group:TPF+surgeron+TPF

Supportan group:Supportan+surgeron+Supportan

TPF control group :surgeron+TPF

Supportan control group:surgeron+Supportan

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) 18 to 80 years old, potentially resectable adenocarcinoma of the Esophagogastric Junction patients, gender not limited; (2) Karnofsky score 60 or more; (3) The first clinical TNM staging, T3 and more than T3 (The Chinese version of on the basis of gastric cancer in 2012 NCCN guidelines); (4) Main organs function is normal, that meet the following criteria: a. HB more than 90g/L (14 days without blood transfusion); b. ANC more than 1.5*10^9 /L; c. PLTmore than 80*10^9/L; e.TBIL less than 1.5*ULN (Upper limit of normal); f.ALT and AST less than 2.5*ULN; g. serumCr more than 1*ULN, The endogenous creatinine clearance more than 50mL/min (Cockcroft-Gault The formula).

Exclusion criteria

Exclusion criteria: (1) Hemodynamic instability; (2) With peritoneal metastasis or extrahepatic distant organ metastasis patients; (3) Alkaline phosphatase more than 100U/L; (4) The primary lesions for ulceration or perforated dangerous of every one of us,not appropriate to accept modified radical treatment of patients with gastric cancer; (5) The digestive tract completeness obstruction; (6) The digestive tract active bleeding; (7) Severe nausea, vomiting, and can not use drug control patients; (8) The absorption of severely malnourished; (9) Chronic disease in acute attack, can not tolerate chemoradiotherapy; (10) Has a history of organ transplantation; (11) There are other patients with neurological or psychiatric disorders or uncooperative; (12) Once patients participated in this study; (13) Life expectancy is shorter than 7 days; (14) Pregnancy or lactation; (15) Allergic to enteral nutrition preparations of known composition of the patients.

Design outcomes

Primary

Measure	Time frame
5-years over survival rate;3-years Disease-free survival(DFS);	—

Secondary

Measure	Time frame
R0-resection rate;Objective response rate (ORR);	—

Countries

China

Contacts

Public ContactQun Zhao

zhaoqun516@126.com+86 13930162111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026